GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI0) » Definitions » Cyclically Adjusted PB Ratio

Cyclacel Pharmaceuticals (STU:UXI0) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 02, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-06-02), Cyclacel Pharmaceuticals's current share price is €8.80. Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €15,003.52. Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Cyclacel Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 2.42. The lowest was 0.01. And the median was 0.19.

STU:UXI0's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.475
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cyclacel Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was €0.218. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €15,003.52 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.09 0.02 - -

Cyclacel Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.80/15003.52
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclacel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cyclacel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.218/134.9266*134.9266
=0.218

Current CPI (Mar. 2025) = 134.9266.

Cyclacel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 21,473.000 100.684 28,775.990
201509 19,246.000 100.392 25,866.705
201512 17,291.000 99.792 23,378.693
201603 14,277.000 100.470 19,173.280
201606 11,714.000 101.688 15,542.922
201609 15,094.000 101.861 19,993.738
201612 13,531.000 101.863 17,923.065
201703 11,985.000 102.862 15,720.987
201706 10,356.000 103.349 13,520.194
201709 9,840.500 104.136 12,750.157
201712 9,196.000 104.011 11,929.352
201803 8,270.000 105.290 10,597.856
201806 7,971.000 106.317 10,115.992
201809 7,112.000 106.507 9,009.743
201812 4,474.667 105.998 5,695.883
201903 3,884.000 107.251 4,886.270
201906 3,480.500 108.070 4,345.463
201909 3,144.500 108.329 3,916.542
201912 2,631.750 108.420 3,275.159
202003 2,351.000 108.902 2,912.838
202006 1,180.050 108.767 1,463.860
202009 1,037.400 109.815 1,274.625
202012 1,051.500 109.897 1,290.987
202103 1,062.132 111.754 1,282.364
202106 943.921 114.631 1,111.040
202109 857.537 115.734 999.743
202112 794.238 117.630 911.029
202203 722.286 121.301 803.420
202206 608.000 125.017 656.195
202209 515.904 125.227 555.866
202212 370.942 125.222 399.690
202303 263.000 127.348 278.652
202306 167.698 128.729 175.772
202309 75.962 129.860 78.926
202312 8.439 129.419 8.798
202403 -24.756 131.776 -25.348
202406 8.212 132.554 8.359
202409 -6.474 133.029 -6.566
202412 -3.747 133.157 -3.797
202503 0.218 134.927 0.218

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cyclacel Pharmaceuticals  (STU:UXI0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cyclacel Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Jalan Kerinchi, Level 10, Tower, Avenue 5, No. 8, Kuala Lumpur, SGR, MYS, 592000
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

Cyclacel Pharmaceuticals Headlines

No Headlines